...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biomaterials Science >Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy
【24h】

Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy

机译：Sorafenib和GPC3 siRNA与PEI改性脂质体进行肝癌治疗的Codelive

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatocellular carcinoma (HCC) is one of the most common malignancies imposing a serious threat to human health worldwide. To date, the effect of HCC chemotherapy has been limited due to drug resistance. Combination therapy of chemotherapeutic drugs and siRNA represents an emerging strategy that may improve anticancer effects by synergistic actions. The current study was aimed at achieving better HCC treatment via combination therapy, in which PEI-modified liposomes prepared by a thin-film hydration method were used to codeliver sorafenib (SF) and siRNA targeting GPC3 gene (siGPC3). Under optimized experimental conditions, SF and siGPC3 were effectively loaded into liposomes (SF-PL/ siGPC3). SF-PL/siGPC3 with selected sizes and zeta potentials effectively accumulated at tumor sites and entered HCC cells. The two codelivered therapeutic agents exerted good anticancer effects by jointly suppressing the expression of the anti-apoptotic GPC3 gene and the proliferative cyclin D1 gene in HCC. Consequently, the intravenous injection of SF-PL/siGPC3 into nude mice bearing subcutaneous human HepG2 xenografts effectively inhibited tumor growth and also increased the survival rates of animals. These results revealed the great potential of the PEI-modified liposomal nanomedicine carrying SF and siGPC3 to improve HCC treatment.
机译：肝细胞癌（HCC）是世界上最常见的恶性肿瘤之一，全世界对人类健康造成严重威胁。迄今为止，由于耐药性，HCC化学疗法的影响受到限制。化学治疗药物和siRNA的组合治疗代表了一种可能通过协同行为改善抗癌影响的新兴策略。目前的研究旨在通过组合治疗实现更好的HCC处理，其中通过薄膜水合法制备制备的PEI改性脂质体用于Codeliver Sorafenib（SF）和靶向GPC3基因的siRNA（SIGPC3）。在优化的实验条件下，SF和SIGPC3有效地装入脂质体（SF-PL / SIGPC3）中。具有选定尺寸的SF-PL / SIGPC3和Zeta电位有效累积在肿瘤部位和进入HCC细胞。通过联合抑制抗凋亡GPC3基因和HCC增殖细胞周期蛋白D1基因的表达，两种CoMelive治疗剂施加了良好的抗癌效果。因此，静脉注射SF-PL / SIGPC3进入携带皮下人HepG2异种移植物的裸鼠的裸鼠有效地抑制了肿瘤生长，并且增加了动物的存活率。这些结果揭示了培养SF和SIGPC3的PEI改性脂质体纳米医生的巨大潜力，以改善HCC处理。

著录项

  • 来源
    《Biomaterials Science》 |2017年第12期|共12页
  • 作者

    Sun Weitong; Wang Yong; Cai Mingyue; Lin Liteng; Chen Xiaoyan; Cao Zhong; Zhu Kangshun; Shuai Xintao;

  • 作者单位

    Sun Yat Sen Univ Sch Mat Sci &

    Engn PCFM Lab Minist Educ Guangzhou 510275 Guangdong Peoples R China;

    Sun Yat Sen Univ Sch Mat Sci &

    Engn PCFM Lab Minist Educ Guangzhou 510275 Guangdong Peoples R China;

    Guangzhou Med Univ Affiliated Hosp 2 Dept Minimally Invas Intervent Radiol Guangzhou Guangdong Peoples R China;

    Guangzhou Med Univ Affiliated Hosp 2 Dept Minimally Invas Intervent Radiol Guangzhou Guangdong Peoples R China;

    Sun Yat Sen Univ Sch Mat Sci &

    Engn PCFM Lab Minist Educ Guangzhou 510275 Guangdong Peoples R China;

    Sun Yat Sen Univ Sch Engn Dept Biomed Engn Guangzhou 510006 Guangdong Peoples R China;

    Guangzhou Med Univ Affiliated Hosp 2 Dept Minimally Invas Intervent Radiol Guangzhou Guangdong Peoples R China;

    Sun Yat Sen Univ Sch Mat Sci &

    Engn PCFM Lab Minist Educ Guangzhou 510275 Guangdong Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分子生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号